Twist Bioscience Corporation Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 177.00K shares, a 94.51% increase year-over-year.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 78.00K shares, a 13.04% increase year-over-year.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 15.00K shares, a 91.12% decline year-over-year.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 155.00K shares, a 26.02% increase year-over-year.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 484.00K shares, a 26.04% increase from fiscal 2024.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 384.00K shares, a 225.42% increase from fiscal 2023.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 118.00K shares, a 75.62% decline from fiscal 2022.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 484.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 177.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-03 | 425.00K shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 78.00K shares derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-05-04 | 339.00K shares derived: sum of 4 quarters · filed 2026-05-04 |
| 2025-12-31 | 15.00K shares 10-Q/A · filed 2026-02-26 | 330.00K shares derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-09-30 | 155.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-17 | 484.00K shares 10-K · filed 2025-11-17 |
| 2025-06-30 | 91.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-04 | 452.00K shares derived: sum of 4 quarters · filed 2025-08-04 |
| 2025-03-31 | 69.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-05 | 495.00K shares derived: sum of 4 quarters · filed 2025-05-05 |
| 2024-12-31 | 169.00K shares 10-Q · filed 2025-02-03 | 495.00K shares derived: sum of 4 quarters · filed 2025-02-03 |
| 2024-09-30 | 123.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-11-18 | 384.00K shares 10-K · filed 2024-11-18 |
| 2024-06-30 | 134.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-02 | 277.00K shares derived: sum of 4 quarters · filed 2024-08-02 |
| 2024-03-31 | 69.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-02 | 187.00K shares derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-12-31 | 58.00K shares 10-Q · filed 2024-02-02 | 141.00K shares derived: sum of 4 quarters · filed 2024-02-02 |
| 2023-09-30 | 16.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-21 | 118.00K shares 10-K · filed 2023-11-21 |
| 2023-06-30 | 44.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-07 | |
| 2023-03-31 | 23.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-08 | |
| 2022-12-31 | 35.00K shares 10-Q · filed 2023-02-07 | |
| 2022-09-30 | 484.00K shares 10-K/A · filed 2023-06-05 | |
| 2019-09-30 | 139.61K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-13 | 331.20K shares 10-K · filed 2019-12-13 |
| 2019-06-30 | 131.58K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-09 | |
| 2019-03-31 | 11.18K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-02 | |
| 2018-12-31 | 48.84K shares 10-Q · filed 2019-02-11 | |
| 2018-09-30 | 62.86K shares 10-K · filed 2019-12-13 | |
| 2017-09-30 | 32.59K shares 10-K · filed 2019-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |